Skip to main content

Paolini John F.'s Form 4 filing

Kiniksa Pharmaceuticals International, plc (KNSA) · filed Mar 4, 2026

Accession no.
0001741533-26-000002
Filed
Mar 4, 2026
Trade date
Mar 2, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.79M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Paolini John F.CIK 0001741533Officer (CHIEF MEDICAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 2, 2026Class A Ordinary ShareMOption exerciseAcquired+40,000$10.36+$414,400101,324Direct
Mar 2, 2026Class A Ordinary ShareSSaleDisposed−12,063$44.20−$533,184.689,261Direct
Mar 2, 2026Class A Ordinary ShareSSaleDisposed−22,223$44.88−$997,368.2467,038Direct
Mar 2, 2026Class A Ordinary ShareSSaleDisposed−5,714$45.92−$262,386.8861,324Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 2, 2026Class A Ordinary ShareMOption exerciseDisposed−40,000$0.00$058,424Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)